Annals of Clinical and Translational Neurology (May 2022)

Novel de novo POLR3B mutations responsible for demyelinating Charcot–Marie–Tooth disease in Japan

  • Masahiro Ando,
  • Yujiro Higuchi,
  • Jun‐Hui Yuan,
  • Akiko Yoshimura,
  • Ruriko Kitao,
  • Takehiko Morimoto,
  • Takaki Taniguchi,
  • Mika Takeuchi,
  • Jun Takei,
  • Yu Hiramatsu,
  • Yusuke Sakiyama,
  • Akihiro Hashiguchi,
  • Yuji Okamoto,
  • Jun Mitsui,
  • Hiroyuki Ishiura,
  • Shoji Tsuji,
  • Hiroshi Takashima

DOI
https://doi.org/10.1002/acn3.51555
Journal volume & issue
Vol. 9, no. 5
pp. 747 – 755

Abstract

Read online

Abstract Background Biallelic POLR3B mutations cause a rare hypomyelinating leukodystrophy. De novo POLR3B heterozygous mutations were recently associated with afferent ataxia, spasticity, variable intellectual disability, and epilepsy, and predominantly demyelinating sensorimotor peripheral neuropathy. Methods We performed whole‐exome sequencing (WES) of DNA samples from 804 Charcot–Marie–Tooth (CMT) cases that could not be genetically diagnosed by DNA‐targeted resequencing microarray using next‐generation sequencers. Using WES data, we analyzed the POLR3B mutations and confirmed their clinical features. Results We identified de novo POLR3B heterozygous missense mutations in two patients. These patients presented with early‐onset demyelinating sensorimotor neuropathy without ataxia, spasticity, or cognitive impairment. Patient 1 showed mild cerebellar atrophy and spinal cord atrophy on magnetic resonance imaging and eventually died of respiratory failure in her 50s. We classified these mutations as pathogenic based on segregation studies, comparison with control database, and in silico analysis. Conclusion Our study is the third report on patients with demyelinating CMT harboring heterozygous POLR3B mutations and verifies the pathogenicity of POLR3B mutations in CMT. Although extremely rare in our large Japanese case series, POLR3B mutations should be added to the CMT‐related gene panel for comprehensive genetic screening, particularly for patients with early‐onset demyelinating CMT.